Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/189959
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heerspink, Hiddo J.L. | - |
dc.contributor.author | Stefánsson, Bergur V. | - |
dc.contributor.author | Correa-Rotter, Ricardo | - |
dc.contributor.author | Chertow, Glenn M. | - |
dc.contributor.author | Greene, Tom | - |
dc.contributor.author | Hou, Fan-Fan | - |
dc.contributor.author | Mann, Johannes F.E. | - |
dc.contributor.author | McMurray, John J.V. | - |
dc.contributor.author | Lindberg, Magnus | - |
dc.contributor.author | Rossing, Peter | - |
dc.contributor.author | Sjöström, C. David | - |
dc.contributor.author | Toto, Roberto D. | - |
dc.contributor.author | Langkilde, Anna-Maria | - |
dc.contributor.author | Wheeler, David C. | - |
dc.contributor.author | Cruzado, Josep Ma. | - |
dc.date.accessioned | 2022-10-17T16:37:11Z | - |
dc.date.available | 2022-10-17T16:37:11Z | - |
dc.date.issued | 2020-09-24 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | http://hdl.handle.net/2445/189959 | - |
dc.description.abstract | Background: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. Methods: We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes. Results: The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 participants (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal causes was 0.56 (95% CI, 0.45 to 0.68; P<0.001), and the hazard ratio for the composite of death from cardiovascular causes or hospitalization for heart failure was 0.71 (95% CI, 0.55 to 0.92; P = 0.009). Death occurred in 101 participants (4.7%) in the dapagliflozin group and 146 participants (6.8%) in the placebo group (hazard ratio, 0.69; 95% CI, 0.53 to 0.88; P = 0.004). The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes. The known safety profile of dapagliflozin was confirmed. Conclusions: Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Massachusetts Medical Society | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa2024816 | - |
dc.relation.ispartof | New England Journal of Medicine, 2020, vol. 383, num. 15, p. 1436-1446 | - |
dc.relation.uri | https://doi.org/10.1056/NEJMoa2024816 | - |
dc.rights | (c) Massachusetts Medical Society, 2020 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties del ronyó | - |
dc.subject.classification | Diabetis | - |
dc.subject.classification | Glucòsids | - |
dc.subject.other | Kidney diseases | - |
dc.subject.other | Diabetes | - |
dc.subject.other | Glucosides | - |
dc.title | Dapagliflozin in patients with chronic kidney disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 710372 | - |
dc.date.updated | 2022-10-17T16:37:11Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32970396 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
710372.pdf | 626.78 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.